Karyopharm announces european medicines agency's validation of its type ii variation marketing authorization application for nexpovio® (selinexor) in combination with velcade® (bortezomib) and dexamethasone for the treatment of adult patients with multipl

Newton, mass., april 26, 2021 /prnewswire/ -- karyopharm therapeutics inc. (nasdaq: kpti), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the european medicines agency (ema) has validated the company's type ii variation marketing authorization application (maa), which seeks to expand the currently authorized indication for nexpovio® in the european union to include, in combination with velcade® (bortezomib) and low-dose dexamethasone, the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
KPTI Ratings Summary
KPTI Quant Ranking